These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1810450)

  • 1. BCG therapy for superficial bladder cancer: fundamental aspects.
    Hudson ML; Ratliff TL
    In Vivo; 1991; 5(6):643-6. PubMed ID: 1810450
    [No Abstract]   [Full Text] [Related]  

  • 2. BCG in the management of superficial bladder cancer.
    Robinson MR
    Prog Clin Biol Res; 1985; 185B():161-6. PubMed ID: 3898140
    [No Abstract]   [Full Text] [Related]  

  • 3. BCG therapy of superficial bladder tumors.
    Herr HW
    Prog Clin Biol Res; 1989; 303():369-74. PubMed ID: 2674999
    [No Abstract]   [Full Text] [Related]  

  • 4. BCG immunotherapy in superficial cancer of the bladder.
    Levinson IP; van Blerk PJ
    S Afr J Surg; 1985 Jun; 23(2):53-4. PubMed ID: 3895464
    [No Abstract]   [Full Text] [Related]  

  • 5. BCG in the management of superficial bladder cancer.
    Guinan P; Richardson C; Hanna M; Rubenstein M
    Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [BCG immunotherapy in the treatment of superficial bladder tumors].
    Samodai L; Drinóczy M; Kolozsy Z; Mohácsi L; Dauda G; Porkoláb Z
    Orv Hetil; 1986 Oct; 127(40):2441-6. PubMed ID: 3537907
    [No Abstract]   [Full Text] [Related]  

  • 7. BCG in carcinoma in situ and superficial bladder tumors.
    Lamm DL
    Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
    [No Abstract]   [Full Text] [Related]  

  • 8. BCG in the treatment of bladder cancer: state of the art.
    Morales A
    Prog Clin Biol Res; 1989; 310():3-10. PubMed ID: 2672017
    [No Abstract]   [Full Text] [Related]  

  • 9. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 10. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM; van der Meijden AP; Franssen MP
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract]   [Full Text] [Related]  

  • 11. Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview.
    van der Meijden AP; Debruyne FM; Steerenberg PA; de Jong WH
    Prog Clin Biol Res; 1989; 310():11-33. PubMed ID: 2672011
    [No Abstract]   [Full Text] [Related]  

  • 12. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of BCG immunotherapy in the management of bladder tumors].
    Samodai L; Kiss L; Kolozsy Z; Dauda G; Drinóczy M; Mohácsi L
    Orv Hetil; 1990 Aug; 131(31):1697-702. PubMed ID: 2205825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Superficial bladder tumors. Preliminary results of a prospective study comparing endovesical BCG, adriamycin and thio-tepa].
    Martínez-Piñeiro JA; de la Peña J; Hidalgo L; Cisneros J; Jiménez León J; Machuca J; Perdices C
    Arch Esp Urol; 1985; 38(6):545-53. PubMed ID: 3938633
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
    Lamm DL
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction.
    Lamm DL
    Eur Urol; 1995; 27 Suppl 1():1. PubMed ID: 7750524
    [No Abstract]   [Full Text] [Related]  

  • 18. [A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
    Oda H; Seki N; Nabeshima S; Oda T; Nishio S; Yokoyama M; Iwata H; Takeuchi M; Matsumoto A; Terado T
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2051-5. PubMed ID: 2221929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG in superficial bladder cancer. EORTC Genitourinary Group Monograph 6. Proceedings of a meeting. Kerkrade, The Netherlands, September 7-8, 1988.
    Prog Clin Biol Res; 1989; 310():1-381. PubMed ID: 2771989
    [No Abstract]   [Full Text] [Related]  

  • 20. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.